← boardnext 2026-09
ORIC
ORIC Pharmaceuticalsdistress 3/10 · well-funded / low risk$10.76+0%today-25% from 52w high
Oncology 2
Lead: NSCLC
Revenue
pre-revenue
Liquidity
$147M
Runway
1.3 yrs
Shares 1y
+7%
Price & events
-10.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.1%
1D
+0.3%
1W
+20.8%
1M
+3.2%
3M
-10.3%
6M
-8.8%
1Y
-4.4%
2Y
-37.6%
5Y
-67.7%
All
Overview
- Market Cap
- $1.11B
- Volume
- 156.11K
- 52 Week Range
- $7.47 – $14.41
- Total Shares
- 103.52M
- Float Shares
- 82.72M
- Short %
- 21.58%
- % Held by Insiders
- 5.85%
- % Held by Institutions
- 113.92%
- RVOL
- 0.10x
- Beta
- 1.01
Pipeline stages · 2 programs
ORIC-114 Dose 1, amivantamab, ORIC-114 Dose 2
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ORIC-944, Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets, Apalutamide (Erleada™) 60 mg or 240 mg tablets, Darolutamide (Nubeqa®) 300 mg tablets, Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09 Estimated 50% readout ~2026-10-16 | Phase 1/2 | ORIC-114, Chemotherapy drug | Solid Tumors | — | recruiting |
| 2026-12 Estimated 50% readout ~2026-12-31 | Phase 1 | ORIC-114 Dose 1, amivantamab, ORIC-114 Dose 2 | Solid Tumors, EGFR Exon 20 Insertion Mutations, NSCLC, EGFR-mutated NSCLC | — | recruiting |
| 2025-12 | Phase 1 | ORIC-944, Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets, Apalutamide (Erleada™) 60 mg or 240 mg tablets, Darolutamide (Nubeqa®) 300 mg tablets, Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets | Metastatic Prostate Cancer | 250 | recruiting |
| 2025-03-03 | Phase 1 | ORIC-533 | Relapsed or Refractory Multiple Myeloma | 31 | completed |
Catalyst news & presentations · 10
- 2026Guided 40%trial initiationsecondaryPhase 3ORIC-114 · Initiate Phase 3 trial(s) in EGFR exon20, HER2 exon20, and/or atypical EGFR mutationsSEC 8-K
- 2026-08-11earningsEarningsEarnings releaseyahoo
- mid-2026readoutPhase 1enozertinib · Next Phase 1b update in 1L EGFR exon20 and 1L EGFR PACCSEC 8-K
- 1H 2026trial initiationsecondaryPhase 3rinzimetostat · First Phase 3 trial (Himalayas-1) in combination with darolutamideSEC 8-K
- 1H 2026trial initiationsecondaryPhase 3ORIC-944 · First Phase 3 trial initiationSEC 8-K
- mid-2026readoutORIC-114 · 1L EGFR exon 20 combination with SC amivantamab and 1L EGFR atypical dataSEC 8-K
- early 2026trial initiationsecondaryORIC-944 · Expected to enter pivotal studySEC 8-K
- 2H 2025readoutPhase 2ORIC-114 · Comprehensive data update including 1L EGFR exon20, 2L+ atypical EGFR, 2L EGFR exon20, 2L+ HER2 exon20SEC 8-K
- 1H 2025readoutPhase 1ORIC-944 · Dose escalation data in combination with apalutamide and darolutamideSEC 8-K
- January 13, 2025conferencedata presentationsecondaryPresented at 43rd Annual J.P. Morgan Healthcare ConferenceSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $20 (+89% upside) · 14 analysts
- 2026-06-08HC Wainwright & Co.Buy
- 2026-05-15Goldman SachsBuy
- 2026-05-05CitigroupBuy
- 2026-04-02HC Wainwright & Co.Buy
- 2026-04-01WedbushOutperform
- 2026-03-13HC Wainwright & Co.Buy
Competitors — NSCLC
- PFEPFIZER INC$142.2B · D3
- RVMDRevolution Medicines, Inc.$40.3B · D1
- IDYAIDEAYA Biosciences, Inc.$3.0B · D3
- AVBPArriVent BioPharma, Inc.$1.4B · D1
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- VSTMVerastem, Inc.$515M · D5
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- BDTXBlack Diamond Therapeutics, Inc.$104M · D5
- MAIAMAIA Biotechnology, Inc.$78M · D5
- NUVLNuvalent, Inc.— · D1
Recent news
- 2026-07-21ORIC Pharmaceuticals starts global Phase 3 tria... - Pluang
- 2026-07-21ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen Bull Case (NASDAQ:ORIC) - Seeking Alpha
- 2026-07-20Discipline and Rules-Based Execution in ORIC Response - Stock Traders Daily
- 2026-07-20ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 - Yahoo! Finance Canada
- 2026-07-20ORIC® Pharmaceuticals Announces Three Presentations at the - GlobeNewswire
- 2026-07-20ORIC® Pharmaceuticals Announces Three Presentations at the - GlobeNewswire
- 2026-07-20ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 - Yahoo Finance
- 2026-07-16How ORIC’s Global Phase 3 Rinzimetostat Trial with Bayer’s NUBEQA Has Changed Its Investment Story (ORIC) - Sahm
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.